{"id":"clofarabine-iv-formulation","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Neutropenia"},{"rate":"30-50%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Infection"},{"rate":"5-20%","effect":"Febrile neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Clofarabine works by incorporating into DNA and causing DNA strand breaks, which triggers apoptosis in cancer cells. This mechanism is particularly effective against leukemia cells, which have a high rate of cell division.","oneSentence":"Clofarabine is a nucleoside analog that interferes with DNA synthesis, leading to cell death in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:23.099Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric and adult patients"},{"name":"Relapsed or refractory acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT00042341","phase":"PHASE2","title":"Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2002-05","conditions":"Leukemia, Lymphoblastic, Acute, Pediatric","enrollment":60},{"nctId":"NCT00042354","phase":"PHASE2","title":"Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2002-05","conditions":"Leukemia, Myelocytic, Acute, Pediatric","enrollment":40},{"nctId":"NCT00317642","phase":"PHASE3","title":"A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-08","conditions":"Acute Myelogenous Leukemia","enrollment":326},{"nctId":"NCT00044889","phase":"PHASE2","title":"Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2002-05","conditions":"Acute Myelogenous Leukemia","enrollment":40},{"nctId":"NCT01063257","phase":"PHASE1, PHASE2","title":"Clofarabine in High Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2010-04","conditions":"Myelodysplastic Syndrome","enrollment":76},{"nctId":"NCT00125840","phase":"PHASE1","title":"Clofarabine in Adult Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2002-08","conditions":"Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Clolar®","Evoltra®"],"phase":"phase_3","status":"active","brandName":"clofarabine (IV formulation)","genericName":"clofarabine (IV formulation)","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clofarabine is a nucleoside analog that interferes with DNA synthesis, leading to cell death in rapidly dividing cancer cells. Used for Relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric and adult patients, Relapsed or refractory acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}